Clinical research on soluble human matrix lysine 2 in diagnosis and prognosis of chronic heart failure
10.3969/j.issn.1673-4130.2017.22.026
- VernacularTitle:可溶性人基质裂解素2在慢性心力衰竭诊断和预后中的临床研究
- Author:
Lihui TAN
1
;
Chunshi TANG
;
Xinlin LU
;
Wenjiang CHEN
Author Information
1. 湖南省郴州市第四人民医院急诊科
- Keywords:
soluble suppression of tumorigenesis 2;
chronic heart failure;
B-type brain natriuretic peptide;
biomarkers . risk factors for prognosis
- From:
International Journal of Laboratory Medicine
2017;38(22):3144-3147
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relationship between serum soluble human matrix lysine 2 (sST2) with chronic heart failure(CHF) and its clinical value for diagnosis and prognosis of CHF .Methods 60 cases of CHF and 60 cases of non-CHF were selected as the CHF group and control group respectively ,and the CHF group was divided into sST2 low level group and sST2 high level group according to the diagnostic threshold .The ELISA method was used to detect the serum sST 2 level of each group .The CHF group were followed up for 6 months .Then the influence of sST2 on CHF prognosis survival rate was observed .Results There was no statistical difference in age ,gender ,body mass index ,basic disease history ,basic medication situation and blood lipid indexes between the CHF group and control group(P＞0 .05);serum brain natriuretic peptide(BNP) level in the CHF group was obviously higher than that in the control group(P＜0 .01);serum sST2 levels in the CHF group and control group were (55 .08 ± 3 .98)ng/mL and (10 .46 ± 0 .72)ng/mL ,the difference was statistically significant (P＜0 .01) .Serum sST2 was positively correlated with BNP(r=0 .4606 ,P＜0 .01) ,moreover 95% CI was 0 .3066-0 .5911 .When the critical value was 0 .5303 ,the area under curve ,95% CI ,sensitivity ,specificity and likelihood ratio of sST 2 combined BNP detection were 0 .9362 ,0 .8853 -0 .9877 , 85 .00% (73 .43% -92 .90% ) ,98 .33% (91 .06% -99 .96% ) and 50 .00 respectively .The survival curve had statistical difference between the sST2 low level group and sST2 high level group(P=0 .0149) .Conclusion Serum sST2 can be used as a new biomarker for the diagnosis and prognosis of CHF ,and its combined with BNP may have better diagnostic value.
